We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Ok ✕
Shelby Giza is the Director of Business Development for Applications at Space Tango, where she aligns corporate objectives with groundbreaking opportunities in health and technology for space-based research and manufacturing. Shelby bridges strategic vision with tactical implementation, fostering seamless collaboration among internal teams and external partners. Her leadership in advancing best practices for the ideation and production of patient therapeutics in space is instrumental in shaping a thriving low-Earth orbit economy. Working closely with research institutions, industry pioneers, and government stakeholders, Shelby drives partnerships that unlock new opportunities, expanding the space-based science and manufacturing solutions market.
With over 20 years of research experience centered on translational medicine, Shelby delivers evidence-based insights that ensure the design and development of advanced hardware and facilities tailored to the diverse needs of scientific ventures. She has played a pivotal role in the R&D of groundbreaking therapeutics, including NIO752 (currently in multiple Phase I trials for Progressive Supranuclear Palsy and Alzheimer’s), Beovu® (approved in 2019 for Neovascular Age-related Macular Degeneration and Diabetic Macular Edema), and the SYNERGY™ Drug-Eluting Stent (approved in 2015). Shelby’s contributions to innovation extend to mRNA vaccine technology, where she participated in the DARPA ADEPT-PROTECT program at Novartis years before the COVID-19 pandemic. She also brings International Space Station (ISS) user experience, having supported the development of a 3D human muscle tissue chip in collaboration with Space Tango and the Malany Lab at the University of Florida, which flew aboard SpaceX CRS-21.